Effects of SGLT2 inhibitors on cardiac structure and function

Area of Science:

• Cardiology
• Pharmacology

Background:

• Sodium-glucose cotransporter 2 (SGLT2) inhibitors are established treatments for type 2 diabetes.
• Recent studies highlight their cardiovascular benefits, including reducing heart failure events.

Purpose of the Study:

• To review the effects of SGLT2 inhibitors on cardiac remodeling and function.
• To elucidate mechanisms beyond glycemic control.

Main Methods:

• Literature review of clinical trials and mechanistic studies.
• Analysis of data concerning hemodynamic, anti-inflammatory, and metabolic effects.

Main Results:

• SGLT2 inhibitors reduce cardiovascular death and heart failure hospitalizations in high-risk patients, with or without diabetes.
• Empagliflozin shows benefits in heart failure with preserved ejection fraction (HFpEF), primarily reducing hospitalizations.
• Observed benefits extend beyond glucose lowering, involving improved cardiac energy metabolism and reduced inflammation.

Conclusions:

• SGLT2 inhibitors provide significant cardiovascular protection in heart failure patients.
• The mechanisms involve favorable hemodynamic, anti-inflammatory, and metabolic adaptations.
• Further research is needed to fully understand the impact on cardiac remodeling and function.